Agilent appoints Pfizer CSO Mikael Dolsten to board effective Sept. 21

AGILENT TECHNOLOGIES, INC.

Dr. Mikael Dolsten, Pfizer CSO & President of Worldwide R&D and Medical, joins Agilent board.
He co-led Pfizer's collaboration with BioNTech on COMIRNATY (COVID-19 vaccine).
Dolsten brings 30+ years pharma experience and involvement in 30+ drug/vaccine approvals.
He will serve on Audit & Finance and Nominating/Corporate Governance committees.
Board size increased from 10 to 11; Dolsten stands for re-election at 2022 annual meeting.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mikael Dolsten

Director

A · AGILENT TECHNOLOGIES, INC.

Effective: 2021-09-21
Filed: September 23, 2021, 7:59 PM ET

appointed Dr. Mikael Dolsten to fill the vacancy so created, both effective September 21, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mikael Dolsten was appointed as Director at AGILENT TECHNOLOGIES, INC..

Action: appointed
Role: Director

Exact text from the filing

appointed Dr. Mikael Dolsten to fill the vacancy so created, both effective September 21, 2021.

View on SEC.gov

AGILENT TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001564590-21-048719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.